(MENAFNEditorial) The cancers constitute 12% of all malignancies in the world and are prevalent in regions where there is high consumption of alcohol and tobacco. Ever since, Hippocrates the first person to use the word 'cancer and probably the first person to divide tumors into benign and malignant, the modern head and neck oncology has undergone numerous changes over the last centuries.
However, the cradle of head and neck oncology can be traced back to ancient Egypt and Greece with the first tumors treated at that time were either cutaneous and malignancies or cancers on the mucosal surfaces of the oral cavity. By 19th and 20th century, there was rapid development and understanding of head and neck oncology with diagnostic methods and treatment strategies having been developed in these two centuries. The majority of head and neck cancers are called squamous cell carcinomas and there exist tests, and diagnosis in the form of Endoscopy, Panorex films, CT scan, Biopsy, MRI, Blood Tests etc.
Global Head and Neck Cancer Diagnostic Market An overview
The global head and neck cancer diagnostic market is valued at US $7.85 billion in 2016 that is projected to reach the US $14.26 billion by 2021 and is predicted to growth at a significant rate at a CAGR of nearly 11.52% during the forecast period. It is estimated that overall head and neck cancer accounts for more than 50,000 cases annually which are roughly 3% to 5% of all cancer incidences all over the globe. Males are more affected by head and neck cancer than females in the ratio ranging from 2:1 to 4:1.
Read more Info at
MENAFN301602201800490000ID1096407529
--MENAFN301602201800490000ID1096407529-->
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.